Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press282EXPERIMENTAL ONCOLOGYЭКСПЕРИМЕНТАЛЬНАЯ ОНКОЛОГИЯInsulinlike growth factors 1 and 2, and insulinelike growth factor binding proteins 1 and 3 in bone tumorsОпухоли костей и система инсулиноподобных факторов ростаKushlinskiiN. E.КушлинскийН. Е.
Russian Federation
biochimia@mtv-net.ruSolovievYu. N.СоловьевЮ. Н.
Russian Federation
TimofeevYu. S.ТимофеевЮ. С.
Russian Federation
BabkinaI. V.БабкинаИ. В.
Russian Federation
KostylevaO. I.КостылеваО. И.
Russian Federation
BoulytchevaI. V.БулычеваИ. В.
Russian Federation
KuznetsovI. N.КузнецовИ. Н.
Russian Federation
AlievM. D.АлиевМ. Д.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН1106201243535711012022Copyright ©; 2012, Kushlinskii N.E., Soloviev Y.N., Timofeev Y.S., Babkina I.V., Kostyleva O.I., Boulytcheva I.V., Kuznetsov I.N., Aliev M.D.Copyright ©; 2012, Кушлинский Н.Е., Соловьев Ю.Н., Тимофеев Ю.С., Бабкина И.В., Костылева О.И., Булычева И.В., Кузнецов И.Н., Алиев М.Д.2012Kushlinskii N.E., Soloviev Y.N., Timofeev Y.S., Babkina I.V., Kostyleva O.I., Boulytcheva I.V., Kuznetsov I.N., Aliev M.D.Кушлинский Н.Е., Соловьев Ю.Н., Тимофеев Ю.С., Бабкина И.В., Костылева О.И., Булычева И.В., Кузнецов И.Н., Алиев М.Д.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/282

Insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) and insulin-like growth factor binding proteins IGFBP-1, IGFBP-3 were measured by ELISA techniques in blood serum of patients with 113 primary bone tumors. It was found a significant increase of IGF-1, 2 and IGFBP-1, 3 levels in bone tumors, compared to control group; significant increase of IGF-1, 2 levels in malignant bone tumors, compared to benign neoplasms of bones, and significant increase of IGFBP-3 levels in benign neoplasms compared to the malignant bone tumors and control group. Were found a significant differences of levels of these substances, depending on the histological type of cancer.

Иммуноферментными методами исследовали содержание ИФР-1, ИФР-2, ИФРСБ-1 и ИФРСБ-3 в сыворотке крови 113 больных новообразованиями костей. Выявлено достоверное повышение ИФР-1, -2, ИФРСБ-1, -3 при новообразованиях кости по сравнению с контролем; достоверное повышение ИФР-1, ИФР-2 по сравнению с доброкачественными новообразованиями, а также достоверное повышение уровня ИФРСБ-3 при доброкачественных новообразованиях в сравнении со злокачественными и контролем. Обнаружены различия уровней исследуемых веществ в зависимости от гистологического варианта злокачественных опухолей.

insulin-like growth factors (IGF-1IGF-2)insuline-like growth factor binding proteins (IGFBP-1IGFBP-3)bone tumorsинсулиноподобные факторы роста (ИФР-1ИФР-2)ИФР-связывающие белки (ИФРСБ-1ИФРСБ-3)опухоли костиClemmons D.R. Value of insulin-likegrowth factor system markers in the assessment of growth hormone status. Endocrinol. Metab. Clin. North. Am. 2007, v. 36, p. 109-129.Frystyk J. Free insulin-like growth factors - Measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 2004, v. 14, p. 337-375.George Vardatsikos, Anita Sahu, Ashok K. Srivastava. The Insulin-Like Growth Factor Family: Molecular Mechanisms, Redox Regulation, and Clinical Implications, antioxidants & redoxsignaling. Volume 11, Number 5, 2009, 1165. Mary Ann Liebert, Inc.Dupont J., Pierre A., Froment P., Moreau C. The insulin-like growth factor axis in cell cycle progression. Horm. Metab. Res. 2003, v. 35, p. 740-750.Zhuang D., Ceacareanu A.C., Lin Y. et al. Nitric oxide attenuate sinsulin-or IGF-I-stimulated aortics mooth muscle cell motility by decree sing H2O2 levels: Essential role of cGMP. Am. J. Physiol. Heart Circ. Physiol. 2004, v. 286, p. 2103-2112.Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxiainducible factor1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 2002, v. 277, p. 38205-38211.Conover C.A. Insulin-like growth factor-binding proteins and bone metabolism. Am. J. Physiol. Endocrinol. Metab. 2008, v. 294, p. 10-14.Ulaner G.A., Vu T.H., Li T., Hu J.F., Yao X.M., Yang Y. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum. Mol. Genet. 2003, v. 12, p. 535-549.Riggi N., Cironi L., Provero P., Suva M.L., Kaloulis K., Garcia-Echeverria C. Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005, v. 65, p. 11459-11468.Kageyama K., Moriyama T., Hizuka N. et al. Hypoglycemica Associated with Big Insulin-Like Growth Factor II Produced during Developmen of Malignant Gibrous Hisiocytoma. End. J. 2003, v. 50, No. 6, p. 753-758.Rikhof B., de Jong S., Suurmeijer A.J., Meijer C., van der Graaf W.T. The insulin-like growth factor system and sarcomas. J. Pathol. 2009, v. 217, p. 469-482.Samani A.A., Yakar S., Le Roith D., Brodt P. The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights. Endocrine Reviews. 2007, v. 28, No. 1, p. 20-47.Tang Y., Zhang D., Fallavollita L., Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res. 2003, v. 63, p. 1166-1171.Suem Firth, Robertc Baxter. Cellular Actions of the InsulinLike Growth Factor Binding Proteins. Endocrine Reviews. 2002, v. 23, p. 824-854.